ArticleInternational journal of molecular sciences2019
Molecular and Functional Verification of Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) Pluripotency.
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04224207 (Management of Retinitis Pigmentosa by Wharton's Jelly Derived Mesenchymal Stem Cells), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Management of Retinitis Pigmentosa by Wharton's Jelly Derived Mesenchymal Stem Cells: Preliminary Clinical Results
Who cites it
38 citing papers in PubMed, 60 citations in OpenAlex.
- Management of toxic optic neuropathy via a combination of Wharton's jelly-derived mesenchymal stem cells with electromagnetic stimulation.Stem cell research & therapy · 2021Trial
- Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results.Stem cell research & therapy · 2020Trial
- Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton's Jelly Mesenchymal Stem Cells in the Orchestrum.Brain sciences · 2026Review
- Effect of Maternal Age on the Proliferation and Osteogenic Differentiation of Human Umbilical Cord Stem Cells.BioMed research international · 2026Article
- Article
- Review
- Chaperone-assisted E3 ligase-engineered mesenchymal stem cells target hyperglycemia-induced p53 for ubiquitination and proteasomal degradation ameliorates self-renewal.Biological research · 2025Article
- The influence of cell source on the senescence of human mesenchymal stem/stromal cells.Human cell · 2025Review
- Probiotic-Derived P8 Protein: Promoting Proliferation and Migration in Stem Cells and Keratinocytes.International journal of stem cells · 2025Article
- Umbilical Cord Matrix (Wharton Jelly) Mesenchymal Stem Cells in Next-generation Myocardial Repair and Regeneration: Mechanisms and Pre-clinical Evidence.Current cardiology reviews · 2025Review
- Optimization of Culture Media for Human Umbilical Cord-Derived Mesenchymal Stem Cell Production.Stem cells international · 2025Article
- Tissue engineering strategies for spiral ganglion neuron protection and regeneration.Journal of nanobiotechnology · 2024Review
- Deciphering decidual deficiencies in recurrent spontaneous abortion and the therapeutic potential of mesenchymal stem cells at single-cell resolution.Stem cell research & therapy · 2024Article
- Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options.International journal of molecular sciences · 2024Review
- Stem Cell-Based Tissue Engineering Approaches for Diabetic Foot Ulcer: a Review from Mechanism to Clinical Trial.Stem cell reviews and reports · 2024Review
- Stemness properties of SSEA-4+ subpopulation isolated from heterogenous Wharton's jelly mesenchymal stem/stromal cells.Frontiers in cell and developmental biology · 2024Article
- The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review.Frontiers in cell and developmental biology · 2024Review
- Roles of Microenvironment on Mesenchymal Stem Cells Therapy for Osteoarthritis.Journal of inflammation research · 2024Review
- Article
- Management of Retinitis Pigmentosa Via Wharton's Jelly-Derived Mesenchymal Stem Cells or Combination With Magnovision: 3-Year Prospective Results.Stem cells translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The properties of mesenchymal stem cells (MSCs), especially their self-renewal and ability to differentiate into different cell lines, are widely discussed. Considering the fact that MSCs isolated from perinatal tissues reveal higher differentiation capacity than most adult MSCs, we examined mesenchymal stem cells isolated from Wharton's jelly of umbilical cord (WJ-MSCs) in terms of pluripotency markers expression. Our studies showed that WJ-MSCs express some pluripotency markers-such as NANOG, OCT-4, and SSEA-4-but in comparison to iPS cells expression level is significantly lower. The level of expression can be raised under hypoxic conditions. Despite their high proliferation potential and ability to differentiate into different cells type, WJ-MSCs do not form tumors in vivo, the major caveat of iPS cells. Owing to their biological properties, high plasticity, proliferation capacity, and ease of isolation and culture, WJ-MSCs are turning out to be a promising tool of modern regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.